MindWalk Holdings (HYFT) Other Non-Current Assets (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Other Non-Current Assets of $18237.7 for Q2 2026, down 94.83% year-over-year from $352769.8 in Q2 2025, and down 2.65% quarter-over-quarter from $18734.8 in Q1 2026.
MindWalk Holdings (HYFT) Other Non-Current Assets (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Other Non-Current Assets for 7 consecutive years, with $18237.7 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 94.83% year-over-year to $18237.7; the TTM figure through Apr 2026 stood at $18237.7 (down 94.83% YoY), while the FY2026 annual figure was $18237.7, down 94.94% from the prior year.
- Other Non-Current Assets eased to $18237.7 in Q2 2026 per HYFT's latest filing, from $18734.8 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $20.0 million in Q3 2025 and bottomed at $18237.7 in Q2 2026.
- Historically, Other Non-Current Assets has averaged $1.3 million across 5 years, with a median of $281345.1 in 2022.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets surged 5558.29% — and 2026, when it plunged 94.83%.
- MindWalk Holdings' Other Non-Current Assets stood at $260501.8 in 2022, then climbed by 6.16% to $276560.2 in 2023, then increased by 29.74% to $358821.5 in 2024, then sank by 94.78% to $18742.9 in 2025, then slipped by 2.7% to $18237.7 in 2026.
- Business Quant data shows HYFT's Other Non-Current Assets at $18237.7 in Q2 2026, $18734.8 in Q1 2026, and $18742.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 18,237.65 |
| Jan 31, 2026 | 18,734.81 |
| Oct 31, 2025 | 18,742.85 |
| Jul 31, 2025 | 20.04 Mn |
| Apr 30, 2025 | 352,769.80 |
| Jan 31, 2025 | 343,760.30 |
| Oct 31, 2024 | 358,821.46 |
| Jul 31, 2024 | 354,201.31 |
| Apr 30, 2024 | 350,322.13 |
| Jan 31, 2024 | 353,586.87 |
| Oct 31, 2023 | 276,560.21 |
| Jul 31, 2023 | 241,992.83 |
| Apr 30, 2023 | 245,364.33 |
| Jan 31, 2023 | 240,211.79 |
| Oct 31, 2022 | 260,501.82 |
| Jul 31, 2022 | 286,129.98 |
| Apr 30, 2022 | 291,345.84 |
| Jan 31, 2022 | 126,413.06 |
| Oct 31, 2021 | 139,997.05 |
| Jul 31, 2021 | 66,746.61 |